Astrazeneca PLC (NYSE:AZN) has been given an average recommendation of “Hold” by the thirty brokerages that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $33.68.

Several research firms have recently issued reports on AZN. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Liberum Capital lowered shares of Astrazeneca PLC from a “buy” rating to a “hold” rating in a report on Thursday, September 14th. BNP Paribas upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Pareto Securities upgraded shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Finally, Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th.

A number of large investors have recently bought and sold shares of the business. Fulton Bank N.A. grew its position in Astrazeneca PLC by 18.2% in the 3rd quarter. Fulton Bank N.A. now owns 42,916 shares of the company’s stock worth $1,454,000 after purchasing an additional 6,598 shares during the period. MPS Loria Financial Planners LLC bought a new stake in Astrazeneca PLC in the 2nd quarter worth approximately $250,000. Intl Fcstone Inc. grew its position in Astrazeneca PLC by 146.9% in the 2nd quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after purchasing an additional 19,365 shares during the period. WFG Advisors LP grew its position in Astrazeneca PLC by 36.0% in the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the period. Finally, Rikoon Group LLC grew its position in Astrazeneca PLC by 1.3% in the 2nd quarter. Rikoon Group LLC now owns 35,780 shares of the company’s stock worth $1,219,000 after purchasing an additional 450 shares during the period. 14.17% of the stock is owned by institutional investors and hedge funds.

Shares of Astrazeneca PLC (AZN) traded down 0.12% during mid-day trading on Wednesday, hitting $34.59. The stock had a trading volume of 2,771,250 shares. The firm has a market cap of $87.58 billion, a PE ratio of 22.69 and a beta of 0.76. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The stock’s 50-day moving average price is $32.20 and its 200-day moving average price is $32.21.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. During the same period in the previous year, the firm posted $0.83 EPS. The business’s revenue was down 9.9% on a year-over-year basis. On average, analysts anticipate that Astrazeneca PLC will post $1.91 earnings per share for the current fiscal year.

The business also recently announced a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were given a $0.44 dividend. This represents a yield of 2.98%. The ex-dividend date of this dividend was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/astrazeneca-plc-azn-receives-consensus-rating-of-hold-from-brokerages.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.